Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | CHKA | P35790 | 2/20 | 0.40 |
| ▸ | CHKB | Q9Y259 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 3/20 | 0.40 |
| ▸ | PDE1A | P54750 | 3/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | LITAF | Q99732 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4097727 | 0.82 | CNR1 (0.45) | SMN1; SMN2CNR1PDE5APDE1APDE1B | |
| SCHEMBL4102377 | 0.81 | CNR1 (0.42) | SMN1; SMN2CNR1CHKACHKBPDE5A | |
| SCHEMBL1689140 | 0.77 | CNR1 (0.46) | CNR1CHKAUSP2CYP1A2ALDH1A1 | |
| SCHEMBL4520124 | 0.76 | DRD1 (0.53) | CNR1PDE5APDE1APDE1BPDE1C | |
| SCHEMBL4520425 | 0.75 | CNR1 (0.38) | CNR1CHKAPDE5APDE1APDE1B | |
| SCHEMBL3175346 | 0.75 | DRD1 (0.39) | CNR1CHKACTSLFLT3GRM1 | |
| SCHEMBL3175337 | 0.75 | DRD1 (0.39) | CNR1CHKACTSLFLT3GRM1 | |
| SCHEMBL5438383 | 0.74 | RAB9A (0.45) | CNR1GRM1 | |
| SCHEMBL4515827 | 0.74 | CNR1 (0.39) | CNR1CHKAPDE5APDE1APDE1B | |
| SCHEMBL4530016 | 0.74 | CNR1 (0.39) | CNR1CHKAPDE5APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2009-09-17 | — | — | US | claimed |
| EP-1888586-A2 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2008-02-20 | — | — | EP | claimed |
| WO-2006120481-A2 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-16 | — | — | WO | claimed |
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2009-09-17 | — | — | US | disclosed |
| EP-1888586-A2 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006120481-A2 | 2,3-SUBSTITUTED FUSED BICYCLIC PYRIMIDIN-4(3H)-ONES WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233947-A1 | 2,3-Substituted fused bicyclic pyrimidin-4(3H)-ones which modulating the function of the vanilloid -1 receptor (VR1) | TRPV1, TRPV2, TRPV3 | SMN1; SMN2 2923/4885CNR1 30/4885CHKA 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.